China SXT Pharmaceuticals SXTC Revenue Breakdown

NASDAQ SXTC
$0.05 -0.02 (-34.25%)
At close: Oct 22, 2026 · 4:00 PM EDT
Annual revenue breakdowns for China SXT Pharmaceuticals, fiscal 2022 to 2026, as reported in its filings.
Annual history

China SXT Pharmaceuticals Revenue by Product & Service

Years FY 2022–2026
Lines 4
FY 2026 Total $1.14M

Regular Tcmp was China SXT Pharmaceuticals’s largest product and service line in fiscal 2026, bringing in $1.08M of $1.14M (95%).

China SXT Pharmaceuticals revenue by product and service, fiscal 2022 to 2026
Product and Service FY 2022 FY 2023 FY 2024 FY 2025 FY 2026
Regular Tcmp — — $1.44M $1.08M
Advanced Tcmp — — $258.42K $49.52K
Revenue Generated From Related Parties $33.62K $27.76K — $41
Others — — $40.03K $7.14K
Total $1.97M $1.93M $1.74M $1.14M
Totals include 1 discontinued line from earlier reporting.

China SXT Pharmaceuticals revenue by product and service: what the figures show

China SXT Pharmaceuticals brought in $1.14M from its four product and service lines in fiscal 2026, the year ended March 31, 2026. China SXT Pharmaceuticals regrouped these lines after fiscal 2025, so the total does not compare directly with that year's $1.74M. Regular Tcmp was the largest at $1.08M (95.0%), ahead of Advanced Tcmp at $49.52K (4.4%) and Others at $7.14K (0.6%). The remaining line, Revenue Generated From Related Parties, brought in $41.

Compared with fiscal 2025, Regular Tcmp fell 25.0% to $1.08M and Advanced Tcmp fell 80.8% to $49.52K.

China SXT Pharmaceuticals began breaking out Regular Tcmp in fiscal 2025, Advanced Tcmp in fiscal 2025 and Others in fiscal 2025. China SXT Pharmaceuticals stopped reporting Revenues Generated From Third Parties as a separate line after fiscal 2024, when it brought in $1.90M.

Questions

China SXT Pharmaceuticals Revenue Breakdown FAQ

How does China SXT Pharmaceuticals make money?

China SXT Pharmaceuticals (SXTC) reports its revenue by product and service. In fiscal 2026, Regular Tcmp was its largest product and service line, bringing in $1.08M (95.0% of the total), followed by Advanced Tcmp at $49.52K (4.4%).

What is China SXT Pharmaceuticals' largest product and service line?

Regular Tcmp was China SXT Pharmaceuticals' largest product and service line in fiscal 2026, bringing in $1.08M, or 95.0% of the $1.14M total across its four product and service lines.

Where does this revenue breakdown data come from?

Every figure comes from China SXT Pharmaceuticals' annual financial filings, as reported. Each line keeps the name China SXT Pharmaceuticals gives it, and years follow its fiscal calendar.

How far back does China SXT Pharmaceuticals' revenue breakdown go?

China SXT Pharmaceuticals' revenue by product and service goes back to fiscal 2022, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.